A Phase I, Single Dose, Parallel-Group Study To Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function.

Trial Profile

A Phase I, Single Dose, Parallel-Group Study To Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function.

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Dec 2016

At a glance

  • Drugs Crizotinib (Primary)
  • Indications Neuroblastoma; Non-small cell lung cancer; Solid tumours
  • Focus Pharmacokinetics
  • Acronyms Study 1020
  • Sponsors Pfizer
  • Most Recent Events

    • 29 Dec 2016 Results assessing effects of varying degrees of renal impairment on crizotinib pharmacokinetics from PROFILE 1001, PROFILE 1005 and Study 1020 trials published in the Clinical Drug Investigation
    • 01 Aug 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Jun 2012 Planned end date changed from 1 Oct 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top